# <u>Motilal Oswal</u>

<b>P&amp;G Hygiene and Hea</b>	Ithcare
--------------------------------	---------

S&P CNX
11,069
PG IN
32
324.3 / 4.5
11000 / 8714
-1/-4/2
68
29.4

		(	
Y/E June	<b>2019</b> E	2020E	2021E
Net Sales	28.6	33.2	39.4
EBITDA	6.7	8.3	10.5
PAT	4.4	5.4	6.8
EPS (INR)	134.4	167.0	209.9
Gr. (%)	18.0	24.3	25.7
BV/Sh (INR)	289.9	341.7	406.9
RoE (%)	50.0	53.0	56.1
RoCE (%)	51.6	54.6	57.7
P/E (x)	74.3	59.8	47.6

Financials & Valuations (INR b)

Estimate change	Ļ
TP change	Ļ
Rating change	

34.5

P/BV (x)

29.2

24.6

#### **CMP: INR9,990**

**TP:INR9,800(-2%)** 

Neutral

- Sales momentum sustains; material cut in EPS forecasts on major margin miss
  - Net sales grew strongly for the second straight quarter at 16.2% YoY to INR8.2b (our estimate: INR8.3b) in 2QFY19 (FY ending June). However, EBITDA declined by 9% YoY to INR1.9b (our estimate: INR2.4b) and adj. PAT was down by 5.4% YoY to INR1.2b (our estimate: INR1.5b).
  - Gross margin shrank 460bp YoY to 55.5%, which can be attributed to a combination of factors, such as (a) high commodity inflation levels, as also witnessed by peers so far in the Dec'18 results, (b) 10% price cuts in *Whisper Choice Ultra* and (c) absence of input tax credit under GST for sanitary napkins. EBITDA margin shrank 650bp YoY to 23.4%, led by higher ad spends (+140bp YoY fourth straight quarter of sharp increase YoY), employee cost (+40bp YoY) and other expenses (+10bp YoY).
  - **1HFY19 performance:** Net sales were up by 18.2% YoY to INR16.1b, EBITDA rose 0.8% YoY to INR4b and PAT grew 5.0% YoY to INR2.6b.
  - Negative net working capital increased by ~60% both YoY and over March, as the increase in creditor days offset the rise in other components.
    - Valuation view: Changes to the model have resulted in a 16.4%/12.8%/8.4% reduction in our EPS estimate for FY19/20/21. Absence of input tax credit and price reduction will have an impact on margins in the subsequent quarters as well. Two factors make PG an attractive long-term core holding: (1) huge category growth potential in the feminine hygiene segment (~70% of sales) and potential for market share growth because of its considerable moats and (2) potentially huge margin gains from premiumization over the longer term in feminine hygiene. However, while PG remains a long-term pick, valuations of 59.8x FY20E EPS are expensive. Target multiple of 52x Dec'20E EPS (10% discount to 3 year average) results in TP of INR9,800. Maintain **Neutral**.

V/E lune		EV4	0			EV4	0		EV4.0	EV40E	EV40	Man
Y/E June		FY1	.ð			FY1	.9		FY18	FY19E	FY19	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Net Sales	6,576	7,042	5,689	5,247	7,918	8,181	6,514	6,010	24,553	28,623	8,309	-1.5%
YoY Change (%)	9.5	9.5	-0.9	4.3	20.4	16.2	14.5	14.6	5.8	16.6	18.0	
Gross profit	3,804	4,235	3,641	3,387	4,766	4,542	3,693	3,457	15,066	16,458	5,126.7	
Margin (%)	57.8	60.1	64.0	64.6	60.2	55.5	56.7	57.5	61.4	57.5	61.7	
EBITDA	1,875	2,102	1,464	839	2,096	1,912	1,433	1,257	6,280	6,698	2,368	-19.2%
Growth	24.0	-8.0	-4.8	-36.0	11.8	-9.0	-2.1	49.7	-5.5	6.7	13	
Margins (%)	28.5	29.9	25.7	16.0	26.5	23.4	22.0	20.9	25.6	23.4	28.5	
Depreciation	128	135	137	123	121	123	130	132	524	506	170	
Interest	4	5	4	41	4	5	6	6	53	21	10	
Other Income	35	71	66	68	96	117	115	121	241	448	110	
РВТ	1,777	2,033	1,307	744	2,066	1,901	1,412	1,240	6,025	6,619	2,298	-17.3%
Тах	622	721	475	298	716	660	484	390	2,160	2,250	793	
Rate (%)	35.0	35.5	36.3	40.1	34.7	34.7	34.3	31.5	35.8	34.0	34.5	
Adj PAT	1,156	1,312	832	445	1,350	1,241	928	849	3,746	4,368	1,505	-17.5%
YoY Change (%)	10.6	-12.9	-16.5	-42.9	16.8	-5.4	11.4	90.6	-13.4	16.6	14.7	
Margins (%)	17.6	18.6	14.6	8.5	17.1	15.2	14.2	14.1	15.3	15.3	18.1	

E: MOSL Estimates

Vishal Punmiya – Research Analyst (Vishal.Punmiya@MotilalOswal.com); +91 22 3980 4261

Krishnan Sambamoorthy – Research Analyst (Krishnan.Sambamoorthy@MotilalOswal.com); +91 22 3982 5428

Investors are advised to refer through important disclosures made at the last page of the Research Report.


Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

#### Exhibit 1: Changes in our model have led to EPS cut of 16.4%/12.8% for FY19/20

Change in Estimates	New			Old			Change			
	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E	
Net Sales	28,623	33,201	39,438	29,119	33,580	39,885	-1.7%	-1.1%	-1.1%	
EBITDA	6,698	8,300	10,530	8,070	9,555	11,487	-17.0%	-13.1%	-8.3%	
Adjusted PAT	4,368	5,428	6,821	5,228	6,226	7,451	-16.4%	-12.8%	-8.4%	

Source: Company, MOSL





Source: Company, MOSL

Source: Company, MOSL

## **Financials and Valuations**

Standalone - Income Statement Y/E June	FY15	FY16	FY17	FY18	FY19E	FY20E	Million) FY21E
Total Income from Operations	-	_			-		
•	<b>23,338</b> 13.8	<b>22,754</b> -2.5	<b>23,204</b> 2.0	<b>24,553</b> 5.8	<b>28,623</b> 16.6	<b>33,201</b> 16.0	<b>39,438</b> 18.8
Change (%) Raw Materials	9,209	8,848	9,150	9,487	12,165	13,779	15,775
% of Sales	39.5	38.9	39.4	38.6	42.5	41.5	40.0
Employees Cost	1,133	1,174	1,141	1,152	1,317	1,494	1,735
% of Sales	4.9	5.2	4.9	4.7	4.6	4.5	4.4
Other Expenses	8,152	6,674			8,444	9,628	11,398
% of Sales	34.9	29.3	6,267 27.0	7,634 31.1	29.5	29.0	28.9
Total Expenditure	<u> </u>	16,696	16,558	18,273	29.5 <b>21,925</b>		28.9 28,908
% of Sales	79.2	73.4	71.4	74.4	76.6	<b>24,901</b> 75.0	73.3
EBITDA	4,844	6,059	<b>6,646</b>		6,698	8,300	10,530
	20.8	26.6	28.6	<b>6,280</b> 25.6	23.4	25.0	26.7
Margin (%) Depreciation	525	517	597	524	506	617	748
EBIT	4,319	5,542	6,049	5,756		7,683	9,782
					6,192		
Int. and Finance Charges Other Income	57 	63 876	104 773	53 241	21 448	30 572	33 587
PBT bef. EO Exp.	5,008	6,355	6,718	5,944	6,619	8,225	10,335
	<b>5,008</b> 0	0	0,718	-82	0,019	<b>8,225</b>	
EO Items		-	-		6 610		0
PBT after EO Exp.	5,008	6,355	6,718	<b>5,862</b>	6,619	8,225	10,335
Total Tax	<u> </u>	2,130	2,390 35.6	2,160 36.8	2,250 34.0	2,796 34.0	3,514 34.0
Tax Rate (%) Reported PAT	30.9 3,461	33.5 <b>4,225</b>	4,327	30.8 3,702		5,428	6,821
•					4,368		
Adjusted PAT Change (%)	<b>3,461</b> 14.6	<b>4,225</b> 22.1	<b>4,327</b> 2.4	3,746	<b>4,368</b> 16.6	<b>5,428</b> 24.3	<b>6,821</b> 25.7
Margin (%)	14.8	18.6	18.6	-13.4 15.3	15.3	16.3	17.3
	14.0	10.0	10.0	15.5	13.5	10.5	17.5
Standalone - Balance Sheet							Million)
Y/E June	FY15	FY16	FY17	FY18	FY19E	FY20E	FY21E
Equity Share Capital	325	325	325	325	325	325	325
Total Reserves Net Worth	13,133 <b>13,457</b>	16,193	4,937	7,730 <b>8,055</b>	9,085 <b>9,409</b>	10,767	12,882
Deferred Tax Liabilities	-40	<b>16,518</b> -89	<b>5,261</b> -263	-230	-253	<b>11,092</b> -278	<b>13,207</b> -306
Total Loans	-40	-89	-203	-230	-255	-278	-500
Capital Employed	13,418	16,428	4,999	7,825	9,156	<b>10,814</b>	12,901
Gross Block	5,222	5,819		6,612	7,504	8,604	9,748
Less: Accum. Deprn.	2,128	2,645	6,505 3,173	3,169	3,675	4,292	5,040
Net Fixed Assets	3,093	3,174		3,103 3,443	3,075 3,830	4,292	
	390	347	<b>3,332</b> 408	<b>3,443</b> 215	422	4,312	<b>4,708</b> 420
Capital WIP Total Investments	0	<u> </u>	408	215	422	422	420
Curr. Assets, Loans&Adv.	15,962	18,053	8,073	11,308	16,378	19,433	23,565
Inventory Account Receivables	1,191	1,275	1,774	1,236	1,804	2,092	2,485
	1,139	1,496	1,328	1,485	1,804	2,092	2,485
Cash and Bank Balance	6,178	10,732	1,168	3,996	7,824	10,286	13,614
Loans and Advances	7,454	4,550	3,803	4,591	4,947	4,963	4,980
Curr. Liability & Prov.	6,027	<b>5,146</b>	6,815	7,140	11,473	13,354	15,793
Account Payables	3,723	3,241	3,632	4,062	5,120	5,936	7,046
Other Current Liabilities	2,234	1,838	2,625	2,548	2,803	3,083	3,391
Provisions	70	67	558	530	3,550	4,335	5,355
Net Current Assets	9,934	12,907	1,258	4,168	4,905	6,080	7,772
Appl. of Funds E: MOSL Estimates	13,418	16,428	4,999	7,825	9,156	10,814	12,901

E: MOSL Estimates

## **Financials and Valuations**

Ratios							
Y/E June	FY15	FY16	FY17	FY18	FY19E	FY20E	FY21E
Basic (INR)							
EPS	106.5	130.0	133.1	113.9	134.4	167.0	209.9
Cash EPS	122.8	146.1	151.7	131.5	150.2	186.2	233.2
BV/Share	414.6	508.9	162.1	248.2	289.9	341.7	406.9
DPS	0.0	36.0	389.0	40.0	92.9	115.4	145.0
Payout (%)	0.0	27.7	292.2	35.1	69.1	69.0	69.0
Valuation (x)							
P/E	93.8	76.8	75.0	87.7	74.3	59.8	47.6
Cash P/E	81.3	68.4	65.8	75.9	66.5	53.6	42.8
P/BV	24.1	19.6	61.6	40.3	34.5	29.2	24.6
EV/Sales	13.6	13.8	13.9	13.0	11.1	9.5	7.9
EV/EBITDA	65.7	51.8	48.6	51.0	47.2	37.8	29.5
Dividend Yield (%)	0.0	0.4	3.9	0.4	0.9	1.2	1.5
FCF per share	131.4	92.5	123.7	116.3	198.3	175.4	231.4
Return Ratios (%)							
RoE	29.5	28.2	39.7	56.3	50.0	53.0	56.1
RoCE	30.0	28.6	41.0	59.1	51.6	54.6	57.7
Working Capital Ratios							
Asset Turnover (x)	1.7	1.4	4.6	3.1	3.1	3.1	3.1
Inventory (Days)	19	18	24	22	23	23	23
Debtor (Days)	16	19	22	21	23	23	23
Creditor (Days)	47	51	54	57	65	65	65
Leverage Ratio (x)							
Debt/Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Standalone - Cash Flow Statement						(INR	Million)
Y/E June	FY15	FY16	FY17	FY18	FY19E	FY20E	FY21E
РВТ	5,008	6,355	6,718	5,818	6,619	8,225	10,335
Depreciation	525	517	597	524	506	617	748
Net interest expense	-658	-785	-644	-147	-427	-542	-554
Others	212	66	146	225	0	0	0
(Inc)/Dec in WC	1,225	-615	135	466	3,090	1,288	1,636
Taxes	-2,056	-2,013	-2,500	-2,731	-2,250	-2,796	-3,514
CF from Operations	4,256	3,525	4,453	4,155	7,538	6,792	8,652
(Inc)/Dec in FA	10	-523	-438	-381	-1,100	-1,100	-1,142
Free Cash Flow	4,266	3,002	4,015	3,774	6,438	5,692	7,510
(Pur)/Sale of Investments	0	0	0	0	0	0	-1
Others	274	2,770	2,009	115	425	547	559
CF from Investments	284	2,247	1,571	-266	-675	-553	-584
Issue of Shares	0	0	0	0	0	0	0
Inc/(Dec) in Debt	0	0	0	0	0	0	0
Dividend Paid	-893	-1,182	-15,550	-1,055	-3,014	-3,746	-4,707
Interest Paid	-9	-35	-37	-6	-21	-30	-33
Others	-152	0	0	0	0	0	0
CF from Fin. Activity	-1,053	-1,217	-15,587	-1,061	-3,035	-3,776	-4,740
Inc/Dec of Cash	3,487	4,554	-9,564	2,828	3,828	2,463	3,328
Opening Balance	2,691	6,178	10,732	1,168	3,996	7,824	10,287
Closing Balance	6,178	10,732	1,168	3,996	7,824	10,287	13,615

E: MOSL Estimates

### **Corporate profile**

#### **Company description**

Procter & Gamble Hygiene & Health Care Limited (PGHH), a 71% subsidiary of P&G, manufactures, distributes and markets three major brands in India – *Whisper* (sanitary napkins), *Vicks* (balm, cough drops and tablets), and *Old Spice* (aftershave lotion and deodorants). Whisper is the market leader, with ~56% share Indian Feminine Hygiene market, which contributed to ~67% of sales in FY18 (June year-end). Vicks is also the market leader, with over 30% share in the cough, Cold and Hay Fever segment of OTC (over the counter) products.



#### Exhibit 2: Shareholding pattern (%)

	Dec-18	Sep-18	Dec-17
Promoter	70.6	70.6	70.6
DII	10.6	10.1	9.6
FII	3.4	3.7	3.9
Others	15.4	15.6	15.9

Note: FII Includes depository receipts Source: Capitaline

#### Exhibit 3: Top holders

Holder Name	% Holding
Life Insurance Corporation Of India	3.2
Sbi Equity Hybrid Fund	2.1
General Insurance Corporation Of India	1.6

#### Source: Capitaline

#### **Exhibit 4: Top management**

Name	Designation
R A Shah	Chairman
Madhusudan Gopalan	Managing Director
Ishan Sonthalia	Company Secretary

	Director	

EXHIBIT 5. Directors	
Name	Name
Karthik Natarajan	Sonali Dhawan
Pramod Agarwal	A K Gupta*
Shailyamanyu Singh Rathore	Bansi S Mehta*

#### Source: Capitaline

\*Independent

Name	Туре
Ashwin Solanki & Associates	Cost Auditor
Dholakia & Associates LLP	Secretarial Audit
Kalyaniwalla & Mistry LLP	Statutory

Source: Capitaline

#### Exhibit 7: MOSL forecast v/s consensus

EPS (INR)	MOSL forecast	Consensus forecast	Variation (%)
FY19	134.4	142.3	-5.5
FY20	167.0	169.5	-1.5
FY21	209.9	225.7	-7.0

Source: Bloomberg

ΝΟΤΕS

Explanation of Investment Rating		
Investment Rating	Expected return (over 12-month)	
BUY	>=15%	
SELL	<- 10%	
NEUTRAL	< - 10 % to 15%	
UNDER REVIEW	Rating may undergo a change	
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation	

\*In case the recommendation given by the Research Analyst becomes inconsistent with the investment rating legend, the Research Analyst shall within 28 days of the inconsistency, take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Securities Ltd. (MOSL)\* is a SEBI Registered Research Analyst having registration no. INH000000412. MOSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOSL is a subsidiary company of Motilal Oswal Financial Service Ltd. (MOFSL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India (MCX) & National Commodity & Derivatives Exchange Ltd. (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) & National Securities Depository Limited (NSDL) and is member of Association of Mutual Funds of India (AMFI) for Oswal available distribution of financial products. Details of associate entities of Motilal Securities Limited are on the website at http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Securities Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views. **Regional Disclosures (outside India)** 

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

#### Specific Disclosures

- MOSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- MOSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company MOSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- MOSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company MOSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months 5
- MOSL has not received compensation for investment banking/merchant banking/brokerage services from the subject company in the past 12 months MOSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months 8
- MOSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOSL has not engaged in market making activity for the subject company

#### The associates of MOSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
  - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

#### The associates of MOSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-3980 4263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 3080 1000. Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-38281085.

Registration details: MOSL: SEBI Registration: INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL: IN-DP-16-2015; NSDL: IN-DP-NSDL-152-2000; Research Analyst: INH000000412. AMFI: ARN 17397. Investment Adviser: INA000007100. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670) offers PMS and Mutual Funds products. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) offers wealth management solutions. \*Motilal Oswal Securities Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance and IPO products. \*Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. offers Real Estate products. \* Motilal Oswal Private Equity Investment Advisors Pvt. Ltd. offers Private Equity products.

\* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench. The existing registration no(s) of MOSL would be used until receipt of new MOFSL registration numbers.